Regulation of MAPs put out for consultation

Regulation of MAPs put out for consultation

October 20 2017 The Department of Health has issued a consultation on the regulation of medical...

Free flu vaccination campaigns kick off to tackle winter pressures

Free flu vaccination campaigns kick off to tackle winter pressures

October 18 2017 The public are being advised of the availability of free flu vaccinations in a...

State-backed GP indemnity scheme could be in place by early 2019

State-backed GP indemnity scheme could be in place by early 2019

October 18 2017 The Department of Health is planning, to develop a state-backed indemnity scheme...

NICE issues guideline on child abuse and neglect

NICE issues guideline on child abuse and neglect

October 17 2017 A new NICE guideline provides recommendations for health and care professionals...

Vaping should be ‘promoted’ as smoking cessation aid

Vaping should be ‘promoted’ as smoking cessation aid

October 17 2017 Electronic cigarettes should be promoted as a method of stopping smoking, the...

  • Regulation of MAPs put out for consultation

    Regulation of MAPs put out for consultation

    Friday, 20 October 2017 09:30
  • Free flu vaccination campaigns kick off to tackle winter pressures

    Free flu vaccination campaigns kick off to tackle winter pressures

    Wednesday, 18 October 2017 16:06
  • State-backed GP indemnity scheme could be in place by early 2019

    State-backed GP indemnity scheme could be in place by early 2019

    Wednesday, 18 October 2017 16:01
  • NICE issues guideline on child abuse and neglect

    NICE issues guideline on child abuse and neglect

    Tuesday, 17 October 2017 14:50
  • Vaping should be ‘promoted’ as smoking cessation aid

    Vaping should be ‘promoted’ as smoking cessation aid

    Tuesday, 17 October 2017 15:00

adhdDecember 2 2015

Researchers have urged doctors to be cautious if considering prescribing methylphenidate for children or adolescents with attention deficit hyperactivity disorder (ADHD).

A Cochrane review has concluded that the drug may improve teacher-reported ADHD symptoms, teacher-reported general behaviour, and parent-reported quality of life among children and adolescents diagnosed with ADHD. “However, the low quality of the underpinning evidence means that we cannot be certain of the magnitude of the effects.”

The researchers assessed 38 parallel-group trials and 147 cross-over trials, representing over 12,200 patients, and found methylphenidate led to “modest” improvements in ADHD symptoms as a primary outcome. They also found there were improvements in general behaviour and quality of life. However, in all outcomes, the quality of the evidence was judged to be “very low”.

Data for serious adverse events was only reported in nine out of the 185 trials, meaning that while methylphenidate does not appear to be associated with an increased risk of serious adverse events, the quality of the evidence was again very low.

“It was apparent from assessing the included trials that it would have been possible for people involved in the trials to have been aware of which treatment the children were taking,” says Cochrane. “In addition, the reporting of results was not complete in many of the trials, and for some analyses there was variation among trial results.

“Based upon this information, the researchers urge clinicians to be cautious in prescribing methylphenidate, and to weigh up the benefits and risks more carefully.”

Professor Ole Jakob Storebø, a clinical psychologist from the Psychiatric Research Unit in Region Zealand, Denmark, led the team of 18 researchers carrying out the meta-analysis. “This review highlights the need for long-term, large, better-quality randomized trials so that we can determine the average effect of this drug more reliably,” he said.

Co-author Camilla Groth MD added: “This review shows very limited quality evidence for the effects of methylphenidate on children and adolescents with ADHD. Some might benefit, but we still don’t know which patients will do so. Clinicians prescribing methylphenidate must take account of the poor quality of the evidence, monitor treatment carefully, and weigh up the benefits and adverse effects.”

Links:

Cochrane announcement

Cochrane review summary

Ole Jakob Storebø et al. ‘Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)’. Cochrane Library. Published online November 25 2015.

Professional News

October 20 2017 Recruitment to GP training places in Wales has meant 91% of places were filled in 2017, the Welsh Government has announced. The success means that the recruitment campaign ‘This is...
December 10 2015 A doctor may find themselves the subject of an investigation at any time in their career, from medical students to trainee doctors, GPs or consultants. Whether it’s an issue...